Melatonin stimulates glucagon secretion in vitro and in vivo

Journal of Pineal Research

Volumn 50, Issue 3, 2011, Pages 336-344

  Bähr, Ina ^a   Mühlbauer, Eckhard ^b   Schucht, Helena ^a   Peschke, Elmar ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b Saxon Academy of Sciences   (Germany)

Author keywords

Glucagon; Glucose metabolism; Melatonin; Pancreatic cell; Type 2 diabetes

Indexed keywords

GLUCAGON; GLUCAGON RECEPTOR; MELATONIN; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; MESSENGER RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HORMONE ACTION; KNOCKOUT MOUSE; LIVER; LONG TERM CARE; MALE; MOUSE; NONHUMAN; PANCREAS ISLET ALPHA CELL; RADIOIMMUNOASSAY; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; CELL LINE; ELECTROPHORESIS; GLUCAGON; MELATONIN; MICE; RATS; RECEPTOR, MELATONIN, MT1; RECEPTORS, GLUCAGON; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 79952574655     PISSN: 07423098     EISSN: 1600079X     Source Type: Journal    
DOI: 10.1111/j.1600-079X.2010.00848.x     Document Type: Article

References (71)

1. RUDIGER HW. Health problems due to night shift work and jetlag. Internist (Berl) 2004; 45:1021-1025 (in German).
2. DONGA E, VAN DIJK M, VAN DIJK JG et al. A single night of partial sleep deprivation induces insulin resistance in multiple metabolic pathways in healthy subjects. J Clin Endocrinol Metab 2010; 95:2963-2968.
3. YAGGI HK, ARAUJO AB, MCKINLAY JB. Sleep duration as a risk factor for the development of type 2 diabetes. Diabetes Care 2006; 29:657-661.
4. GOTTLIEB DJ, PUNJABI NM, NEWMAN AB et al. Association of sleep time with diabetes mellitus and impaired glucose tolerance. Arch Intern Med 2005; 165:863-867.
5. ANDERSSON EA, HOLST B, SPARSO T et al. MTNR1B G24E variant associates With BMI and fasting plasma glucose in the general population in studies of 22,142 Europeans. Diabetes 2010; 59:1539-1548.
6. PROKOPENKO I, LANGENBERG C, FLOREZ JC et al. Variants in MTNR1B influence fasting glucose levels. Nat Genet 2009; 41:77-81.
7. SPARSO T, BONNEFOND A, ANDERSSON E et al. G-allele of intronic rs10830963 in MTNR1B confers increased risk of impaired fasting glycemia and type 2 diabetes through an impaired glucose-stimulated insulin release: studies involving 19,605 Europeans. Diabetes 2009; 58:1450-1456.
8. TAM CH, HO JS, WANG Y et al. Common polymorphisms in MTNR1B, G6PC2 and GCK are associated with increased fasting plasma glucose and impaired beta-cell function in Chinese subjects. PLoS ONE 2010; 5:e11428.
9. MÜHLBAUER E, PESCHKE E. Evidence for the expression of both the MT1- and in addition, the MT2-melatonin receptor, in the rat pancreas, islet and beta-cell. J Pineal Res 2007; 42:105-106.
10. PESCHKE E, STUMPF I, BAZWINSKY I et al. Melatonin and type 2 diabetes - a possible link? J Pineal Res 2007; 42:350-358.
11. KEMP DM, UBEDA M, HABENER JF. Identification and functional characterization of melatonin Mel 1a receptors in pancreatic beta cells: potential role in incretin-mediated cell function by sensitization of cAMP signaling. Mol Cell Endocrinol 2002; 191:157-166.
12. PESCHKE E, FAUTECK JD, MUSSHOFF U et al. Evidence for a melatonin receptor within pancreatic islets of neonate rats: functional, autoradiographic, and molecular investigations. J Pineal Res 2000; 28:156-164.
13. RAMRACHEYA RD, MULLER DS, SQUIRES PE et al. Function and expression of melatonin receptors on human pancreatic islets. J Pineal Res 2008; 44:273-279.
14. LYSSENKO V, NAGORNY CL, ERDOS MR et al. Common variant in MTNR1B associated with increased risk of type 2 diabetes and impaired early insulin secretion. Nat Genet 2009; 41:82-88.
15. PESCHKE E, BACH AG, MÜHLBAUER E. Parallel signaling pathways of melatonin in the pancreatic beta-cell. J Pineal Res 2006; 40:184-191.
16. STUMPF I, MÜHLBAUER E, PESCHKE E. Involvement of the cGMP pathway in mediating the insulin-inhibitory effect of melatonin in pancreatic beta-cells. J Pineal Res 2008; 45:318-327.
17. BAZWINSKY-WUTSCHKE I, MÜHLBAUER E, WOLGAST S et al. Transcripts of calcium/calmodulin-dependent kinases are changed after forskolin- or IBMX-induced insulin secretion due to melatonin treatment of rat insulinoma beta-cells (INS-1). Horm Metab Res 2009; 41:805-813.
18. PESCHKE E, MÜHLBAUER E, MUSSHOFF U et al. Receptor (MT(1)) mediated influence of melatonin on cAMP concentration and insulin secretion of rat insulinoma cells INS-1. J Pineal Res 2002; 33:63-71.
19. PICINATO MC, HABER EP, CIPOLLA-NETO J et al. Melatonin inhibits insulin secretion and decreases PKA levels without interfering with glucose metabolism in rat pancreatic islets. J Pineal Res 2002; 33:156-160.
20. STUMPF I, BAZWINSKY I, PESCHKE E. Modulation of the cGMP signaling pathway by melatonin in pancreatic beta-cells. J Pineal Res 2009; 46:140-147.
21. PESCHKE E, SCHUCHT H, MÜHLBAUER E. Long-term enteral administration of melatonin reduces plasma insulin and increases expression of pineal insulin receptors in both Wistar and type 2-diabetic Goto-Kakizaki rats. J Pineal Res 2010; 49:373-381.
22. PICINATO MC, HABER EP, CARPINELLI AR et al. Daily rhythm of glucose-induced insulin secretion by isolated islets from intact and pinealectomized rat. J Pineal Res 2002; 33:172-177.
23. MÜHLBAUER E, GROSS E, LABUCAY K et al. Loss of melatonin signalling and its impact on circadian rhythms in mouse organs regulating blood glucose. Eur J Pharmacol 2009; 606:61-71.
24. NISHIDA S, SEGAWA T, MURAI I et al. Long-term melatonin administration reduces hyperinsulinemia and improves the altered fatty-acid compositions in type 2 diabetic rats via the restoration of Delta-5 desaturase activity. J Pineal Res 2002; 32:26-33.
25. RASMUSSEN DD, BOLDT BM, WILKINSON CW et al. Daily melatonin administration at middle age suppresses male rat visceral fat, plasma leptin, and plasma insulin to youthful levels. Endocrinology 1999; 140:1009-1012.
26. WOLDEN-HANSON T, MITTON DR, MCCANTS RL et al. Daily melatonin administration to middle-aged male rats suppresses body weight, intraabdominal adiposity, and plasma leptin and insulin independent of food intake and total body fat. Endocrinology 2000; 141:487-497.
27. PESCHKE E, FRESE T, CHANKIEWITZ E et al. Diabetic Goto Kakizaki rats as well as type 2 diabetic patients show a decreased diurnal serum melatonin level and an increased pancreatic melatonin-receptor status. J Pineal Res 2006; 40:135-143.
28. PESCHKE E, WOLGAST S, BAZWINSKY I et al. Increased melatonin synthesis in pineal glands of rats in streptozotocin induced type 1 diabetes. J Pineal Res 2008; 45:439-448.
29. GRAPENGIESSER E, SALEHI A, QADER SS et al. Glucose induces glucagon release pulses antisynchronous with insulin and sensitive to purinoceptor inhibition. Endocrinology 2006; 147:3472-3477.
30. MEIER JJ, KJEMS LL, VELDHUIS JD et al. Postprandial suppression of glucagon secretion depends on intact pulsatile insulin secretion: further evidence for the intraislet insulin hypothesis. Diabetes 2006; 55:1051-1056.
31. YAMAMOTO H, NAGAI K, NAKAGAWA H. Role of SCN in daily rhythms of plasma glucose, FFA, insulin and glucagon. Chronobiol Int 1987; 4:483-491.
32. RUITER M, LA FLEUR SE, VAN HEIJNINGEN C et al. The daily rhythm in plasma glucagon concentrations in the rat is modulated by the biological clock and by feeding behavior. Diabetes 2003; 52:1709-1715.
33. KOSA E, MAUREL D, SIAUD P. Effects of pinealectomy on glucagon responsiveness to hypoglycaemia induced by insulin injections in fed rats. Exp Physiol 2001; 86:617-620.
34. RODRIGUEZ V, MELLADO C, ALVAREZ E et al. Effect of pinealectomy on liver insulin and glucagon receptor concentrations in the rat. J Pineal Res 1989; 6:77-88.
35. SCHMID SM, HALLSCHMID M, JAUCH-CHARA K et al. Sleep loss alters basal metabolic hormone secretion and modulates the dynamic counterregulatory response to hypoglycemia. J Clin Endocrinol Metab 2007; 92:3044-3051.
36. SCHMID SM, JAUCH-CHARA K, HALLSCHMID M et al. Mild sleep restriction acutely reduces plasma glucagon levels in healthy men. J Clin Endocrinol Metab 2009; 94:5169-5173.
37. MAHER TD, TANENBERG RJ, GREENBERG BZ et al. Lack of glucagon response to hypoglycemia in diabetic autonomic neuropathy. Diabetes 1977; 26:196-200.
38. JIN X, VON GALL C, PIESCHL RL et al. Targeted disruption of the mouse Mel(1b) melatonin receptor. Mol Cell Biol 2003; 23:1054-1060.
39. LIU C, WEAVER DR, JIN X et al. Molecular dissection of two distinct actions of melatonin on the suprachiasmatic circadian clock. Neuron 1997; 19:91-102.
40. PESCHKE E. Melatonin, endocrine pancreas and diabetes. J Pineal Res 2008; 44:26-40.
41. MA X, ZHANG Y, GROMADA J et al. Glucagon stimulates exocytosis in mouse and rat pancreatic alpha-cells by binding to glucagon receptors. Mol Endocrinol 2005; 19:198-212.
42. GASTALDELLI A, BALDI S, PETTITI M et al. Influence of obesity and type 2 diabetes on gluconeogenesis and glucose output in humans: a quantitative study. Diabetes 2000; 49:1367-1373.
43. RASKIN P, UNGER RH. Effect of insulin therapy on the profiles of plasma immunoreactive glucagon in juvenile-type and adult-type diabetics. Diabetes 1978; 27:411-419.
44. REAVEN GM, CHEN YD, Golay A et al. Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1987; 64:106-110. (Pubitemid 17015886)
45. MULDER H, NAGORNY CL, LYSSENKO V et al. Melatonin receptors in pancreatic islets: good morning to a novel type 2 diabetes gene. Diabetologia 2009; 52:1240-1249.
46. RAVIER MA, RUTTER GA. Glucose or insulin, but not zinc ions, inhibit glucagon secretion from mouse pancreatic alphacells. Diabetes 2005; 54:1789-1797.
47. BACH AG, WOLGAST S, MÜHLBAUER E et al. Melatonin stimulates inositol-1,4,5-trisphosphate and Ca2+ release from INS1 insulinoma cells. J Pineal Res 2005; 39:316-323.
48. PARKER JC, ANDREWS KM, ALLEN MR et al. Glycemic control in mice with targeted disruption of the glucagon receptor gene. Biochem Biophys Res Commun 2002; 290:839-843.
49. QUESADA I, TUDURI E, RIPOLL C et al. Physiology of the pancreatic alpha-cell and glucagon secretion: role in glucose homeostasis and diabetes. J Endocrinol 2008; 199:5-19.
50. SCHWANINGER M, LUX G, BLUME R et al. Membrane depolarization and calcium influx induce glucagon gene transcription in pancreatic islet cells through the cyclic AMP-responsive element. J Biol Chem 1993; 268:5168-5177.
51. GOTO Y, SUZUKI K, ONO T et al. Development of diabetes in the non-obese NIDDM rat (GK rat). Adv Exp Med Biol 1988; 246:29-31.
52. CRYER PE. Hypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes. Diabetologia 2002; 45:937-948.
53. WARD WK, BOLGIANO DC, MCKNIGHT B et al. Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus. J Clin Invest 1984; 74:1318-1328.
54. KANEKO K, SHIROTANI T, ARAKI E et al. Insulin inhibits glucagon secretion by the activation of PI3-kinase in In-R1-G9 cells. Diabetes Res Clin Pract 1999; 44:83-92.
55. GREENBAUM CJ, HAVEL PJ, TABORSKY GJ JR et al. Intra-islet insulin permits glucose to directly suppress pancreatic A cell function. J Clin Invest 1991; 88:767-773.
56. STARKE A, IMAMURA T, UNGER RH. Relationship of glucagon suppression by insulin and somatostatin to the ambient glucose concentration. J Clin Invest 1987; 79:20-24.
57. BARDEN N, LAVOIE M, DUPONT A et al. Stimulation of glucagon release by addition of anti-stomatostatin serum to islets of Langerhans in vitro. Endocrinology 1977; 101:635-638.
58. GRZESKOWIAK R, AMIN J, OETJEN E et al. Insulin responsiveness of the glucagon gene conferred by interactions between proximal promoter and more distal enhancer-like elements involving the paired-domain transcription factor Pax6. J Biol Chem 2000; 275:30037-30045.
59. SCHINNER S, DELLAS C, SCHRODER M et al. Repression of glucagon gene transcription by peroxisome proliferator-activated receptor gamma through inhibition of Pax6 transcriptional activity. J Biol Chem 2002; 277:1941-1948.
60. ROESLER WJ, KHANDELWAL RL. Diurnal variations in the activities of the glycogen metabolizing enzymes in mouse liver. Int J Biochem 1985; 17:81-85.
61. ISHIKAWA K, SHIMAZU T. Daily rhythms of glycogen synthetase and phosphorylase activities in rat liver: influence of food and light. Life Sci 1976; 19:1873-1878.
62. KIDA K, NISHIO T, YOKOZAWA T et al. The circadian change of gluconeogenesis in the liver in vivo in fed rats. J Biochem 1980; 88:1009-1013.
63. STOKKAN KA, YAMAZAKI S, TEI H et al. Entrainment of the circadian clock in the liver by feeding. Science 2001; 291:490-493.
64. RUDIC RD, MCNAMARA P, CURTIS AM et al. BMAL1 and CLOCK, two essential components of the circadian clock, are involved in glucose homeostasis. PLoS Biol 2004; 2:e377.
65. POON AM, CHOY EH, PANG SF. Modulation of blood glucose by melatonin: a direct action on melatonin receptors in mouse hepatocytes. Biol Signals Recept 2001; 10:367-379.
66. AUTHIER F, DESBUQUOIS B. Glucagon receptors. Cell Mol Life Sci 2008; 65:1880-1899.
67. SANTOS A, BLAZQUEZ E. Regulatory effect of glucagon on its own receptor concentrations and target-cell sensitivity in the rat. Diabetologia 1982; 22:362-371.
68. NODA C, SHINJYO F, TOMOMURA A et al. Mechanism of heterologous desensitization of the adenylate cyclase system by glucagon in primary cultures of adult rat hepatocytes. J Biol Chem 1984; 259:7747-7754.
69. AUTHIER F, DESBUQUOIS B, DE GALLE B. Ligand-mediated internalization of glucagon receptors in intact rat liver. Endocrinology 1992; 131:447-457.
70. ABRAHAMSEN N, LUNDGREN K, NISHIMURA E. Regulation of glucagon receptor mRNA in cultured primary rat hepatocytes by glucose and cAMP. J Biol Chem 1995; 270:15853-15857.
71. BURCELIN R, MREJEN C, DECAUX JF et al. In vivo and in vitro regulation of hepatic glucagon receptor mRNA concentration by glucose metabolism. J Biol Chem 1998; 273:8088-8093.